Johnson & Johnson (JNJ) Earnings: Q3 Fiscal 2026 Results and Next Report Date

The quarter ended September 27, 2026 and Johnson & Johnson published the results on October 13, 2026. Revenue and diluted EPS are shown against Q3 fiscal 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Johnson & Johnson reports EPS two ways: GAAP, under the accounting rules every US filer follows, and adjusted, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• GAAP results include a $5.5 billion accrual for the proposed resolution of the ovarian talc litigation, which adjusted EPS excludes.
• Adjusted EPS of $2.59 still includes about $1.0 billion of acquired in-process research and development for Firefly Bio and $0.3 billion of expense for the Sail Biomedicines collaboration.
• Franchise rows are rounded in the supplementary schedule and may not add exactly to the segment totals.

Source: Johnson & Johnson Q3 2026 results, October 13, 2026. Also in the Form 10-Q for the quarter ended September 27, 2026. Figures as reported; checked against the release on November 10, 2026.

How Johnson & Johnson splits revenue in its own release, under its own labels, for Q3 fiscal 2026 against Q3 fiscal 2025. Indented lines are parts of the line above them.

• Johnson & Johnson's Innovative Medicine revenue was $16.8 billion in Q3 fiscal 2026, up 8% from $15.6 billion in Q3 fiscal 2025, 66% of total revenue.
• Johnson & Johnson's MedTech revenue was $8.6 billion in Q3 fiscal 2026, up 3% from $8.4 billion in Q3 fiscal 2025, 34% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

Johnson & Johnson gives full-year guidance in its release, on a non-GAAP basis, as a table of ranges. The headline figures are quoted below.

In its Q3 fiscal 2026 release, Johnson & Johnson said:

“Strong operational performance results in the Company increasing 2026 guidance with estimated reported sales of $101.2 Billion or 7.4% at the midpoint and increasing adjusted EPS* guidance by $0.06 to $11.10 or 2.9% at the midpoint”

Source: Johnson & Johnson Q3 2026 release, Oct 13, 2026.

This is the company's own guidance as of Oct 13, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the JNJ forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

Reported sales and GAAP diluted EPS, each as first reported in that quarter's release.

Johnson & Johnson's next report is scheduled for January 26, 2027. This page will show Q3 fiscal 2026 until those results are out and have been checked against the release.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 fiscal 2026 (this page), reported Oct 13, 2026

Johnson & Johnson reports two segments. In Q3 fiscal 2026 Innovative Medicine (prescription drugs) had sales of $16,757 million, up 7.7%, and MedTech $8,642 million, up 2.5%, for total reported sales of $25,399 million. Oncology was the largest franchise at $7,602 million, followed by Immunology at $4,221 million and Neuroscience at $2,375 million. (Johnson & Johnson Q3 2026 release, Oct 13, 2026; Johnson & Johnson Q3 2026 supplementary sales data and financial schedules, Oct 13, 2026)

Johnson & Johnson's growth came from newer medicines. TREMFYA sales were $2,396 million, up 68.3%, DARZALEX $4,239 million, up 15.4%, and CARVYKTI $710 million, up 35.5%. STELARA, which faces biosimilar competition, fell to $716 million from $1,570 million, which the release says cut Innovative Medicine growth by about 690 basis points. OPSUMIT/OPSYNVI fell to $372 million from $578 million after U.S. generic entrants late in the second quarter of 2026. (Johnson & Johnson Q3 2026 supplementary sales data and financial schedules, Oct 13, 2026; Johnson & Johnson Q3 2026 release, Oct 13, 2026; Johnson & Johnson Form 10-Q, Q3 2026, Oct 21, 2026)

In MedTech, Johnson & Johnson's growth was led by electrophysiology ($1,487 million, up 4.9%), Shockwave ($325 million, up 16.8%), contact lenses ($1,053 million, up 3.5%) and trauma ($844 million, up 6.4%). Surgery sales slipped to $2,528 million from $2,542 million. Johnson & Johnson announced in October 2025 that it would separate its Orthopaedics business and expects the separation to be completed in mid-2027; Orthopaedics sales were $2,345 million in the quarter. (Johnson & Johnson Q3 2026 supplementary sales data and financial schedules, Oct 13, 2026; Johnson & Johnson Q3 2026 release, Oct 13, 2026; Johnson & Johnson Form 10-Q, Q3 2026, Oct 21, 2026)

Johnson & Johnson's U.S. sales grew 9.1% to $14,959 million, while international sales grew 1.5% to $10,440 million. Within international, Europe was $5,405 million, down 0.6%, and Asia-Pacific, Africa was $3,650 million, up 1.0%. Currency reduced total growth by 0.1 points, so operational sales growth was 6.0%. (Johnson & Johnson Q3 2026 supplementary sales data and financial schedules, Oct 13, 2026; Johnson & Johnson Q3 2026 release, Oct 13, 2026)

Johnson & Johnson's GAAP diluted EPS was $0.09 in Q3 fiscal 2026, against adjusted EPS of $2.59. The difference is mostly litigation: Johnson & Johnson recorded a $5.5 billion accrual for the proposed resolution of the ovarian talc litigation, which calls for a $5.5 billion commitment and requires participation of at least 95% of remaining claims. As of the quarter the total talc reserve was approximately $9.0 billion. Adjusted EPS also excludes intangible asset amortization ($1,240 million pre-tax), Orthopaedics separation costs ($369 million), IPR&D impairments ($339 million) and restructuring ($195 million). (Johnson & Johnson Form 10-Q, Q3 2026, Oct 21, 2026; Johnson & Johnson Q3 2026 supplementary sales data and financial schedules, Oct 13, 2026)

Johnson & Johnson's adjusted EPS fell to $2.59 from $2.80 because it does not exclude deal costs such as acquired in-process research and development: about $1.0 billion for the acquisition of Firefly Bio and $0.3 billion for the collaboration with Sail Biomedicines. Research and development expense rose to $4,652 million, 18.3% of sales, from $3,672 million. (Johnson & Johnson Form 10-Q, Q3 2026, Oct 21, 2026; Johnson & Johnson Q3 2026 supplementary sales data and financial schedules, Oct 13, 2026)

Johnson & Johnson's reported effective tax rate was negative 517.6%, because the talc accrual left pre-tax earnings at $34 million; the adjusted effective tax rate was 17.4%, against 19.4% a year earlier. Diluted average shares outstanding were 2,448.6 million, against 2,428.6 million. (Johnson & Johnson Q3 2026 supplementary sales data and financial schedules, Oct 13, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Johnson & Johnson publishes full-year guidance in its release on a non-GAAP basis and does not give GAAP guidance. With Q3 fiscal 2026 it raised 2026 estimated reported sales to a $101.2 billion midpoint (7.4% growth), adjusted operational sales growth to a 6.6% midpoint and adjusted EPS by $0.06 to a $11.10 midpoint (2.9% growth), from $11.04 in July. (Johnson & Johnson Q3 2026 release, Oct 13, 2026)

Johnson & Johnson's 10-Q flags further pressure on older products: it expects STELARA biosimilars to keep reducing STELARA sales, SIMPONI biosimilars entered Europe in the second quarter of 2026 with a potential U.S. entrant later in 2026, and UPTRAVI faces potential generic entrants in 2027. (Johnson & Johnson Form 10-Q, Q3 2026, Oct 21, 2026)

A consensus figure is the average of the models published by the analysts who cover Johnson & Johnson, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Johnson & Johnson's own release and filings put weight on for Q3 fiscal 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning JNJ is on is JNJ a buy or a sell?, what analysts expect next is on the JNJ forecast, and what the company does is on the Johnson & Johnson (JNJ) stock page.

Every number on this page can be traced to a document Johnson & Johnson published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.